Complexion changes oral contraceptive users Results phase IV multicenter trial safety efficacy ethynodiol diacetate mg ethinyl estradiol micrograms open-label phase IV multicenter survey obstetrician-gynecologists efficacy safety low-dose monophasic oral contraceptive ethynodiol diacetate mg ethinyl estradiol micrograms Surveys community-based physicians women patients noticeable complexion changes patients complexion changes three-fourths improvement follow-up questionnaire respondents worsening complexion questionnaires complexion worsening slight degree patient physician first months literature many references condition improvement oral contraceptives report descriptive study clinicians estimate incidence severity complexion changes actual use 